Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Latest ICR News
Breast cancer blood test can predict treatment response
A blood test can predict how well patients with advanced breast cancer will respond to targeted therapies – before treatment begins, according to new research.
The ICR welcomes NHS decision to grant lifesaving prostate cancer drug to men in England
The Institute of Cancer Research, London, has welcomed the announcement that the lifesaving drug abiraterone has been approved for use on the NHS for men in England with prostate cancer that has a high risk of spreading.
New research uncovers critical DNA repair mechanism during cell division
A major advance in cell biology has revealed how our cells safeguard their genetic material during one of the most vulnerable moments in their life cycle. The study identifies a specific protein complex as a central coordinator of DNA repair during cell division.
Tumour samples from the 1950s could help unlock the mystery of rising bowel cancer cases in the under 50s
Tens of thousands of tumour samples which have been stored in the basement of a London hospital for more than 70 years could be the key to unlocking the mystery of why bowel cancer cases are rising in the under 50s, scientists believe.
Researchers at The Institute of Cancer Research, London, and St Marks Hospital are launching a pioneering study to compare bowel cancer specimens from the 1960s with modern-day cancer samples.